1
|
Kim HS, Nam CM, Jang SY, Choi SK, Han M, Kim S, Moneta MV, Lee SY, Cho JM, Novick D, Rha SY. Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea. Cancer Res Treat 2019; 51:1380-1391. [PMID: 30776883 PMCID: PMC6790845 DOI: 10.4143/crt.2018.476] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Accepted: 02/15/2019] [Indexed: 12/13/2022] Open
Abstract
PURPOSE A soft tissue sarcoma (STS) is a rare type of cancer, accounting for 1% of adult solid cancers. The aim of the present study is to determine the incidence of localized and advanced STS in Korean patients, their treatment patterns, and the survival of patients by disease status. MATERIALS AND METHODS The STS patient cohort was defined using National Health Insurance Service medical data from 2002 to 2015. Incidence, distribution, anatomical location of tumors, survival rates (Kaplan-Meyer survival function) and treatment patterns were analyzed by applying different algorithms to the STS cohort containing localized and advanced STS cases. RESULTS A total of 7,813 patients were diagnosed with STS from 2007 to 2014, 4,307 were localized STS and 3,506 advanced STS cases. The total incidence of STS was 2.49 per 100,000 person- years: 1.37 per 100,000 person-years for localized STS and 1.12 per 100,000 person-years for advanced STS. The 5-year survival rate after diagnosis was 56.4% for all STS, 82.4% for localized, and 27.2% for advanced STS. Half of the advanced STS patients (49.98%) received anthracycline-containing chemotherapy as initial treatment after diagnosis. CONCLUSION This study provides insights into localized and advanced STS epidemiology, treatment patterns and outcomes in Korea, which could be used as fundamental data in improving clinical outcomes of STS patients in the future.
Collapse
Affiliation(s)
- Hyo Song Kim
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
| | - Chung Mo Nam
- Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea
| | - Suk-Yong Jang
- Department of Preventive Medicine, Eulji University College of Medicine, Daejeon, Korea
| | - Sun Kyu Choi
- Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea
| | - Minkyung Han
- Department of Public Health, Yonsei University Graduate School, Seoul, Korea
| | - Seonmin Kim
- Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea
| | - Maria Victoria Moneta
- Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain
| | | | | | | | - Sun Young Rha
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
| |
Collapse
|
2
|
Pingping B, Yuhong Z, Weiqi L, Chunxiao W, Chunfang W, Yuanjue S, Chenping Z, Jianru X, Jiade L, Lin K, Zhengdong C, Weibin Z, Chen F, Yang Y. Incidence and Mortality of Sarcomas in Shanghai, China, During 2002-2014. Front Oncol 2019; 9:662. [PMID: 31380289 PMCID: PMC6653066 DOI: 10.3389/fonc.2019.00662] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Accepted: 07/05/2019] [Indexed: 12/13/2022] Open
Abstract
Background: Sarcomas are a heterogeneous group of rare but deadly malignant tumors. The aim of this study was to comprehensively describe the incidence and mortality of sarcomas in Shanghai during 2002-2014. Method: Data were from Shanghai Cancer Registry. All new cases diagnosed with sarcomas and all death records where the cause of death listed as sarcomas were included. The characteristics of sarcomas incidence and mortality were analyzed. Age-standardized rates (ASRs) were adjusted by the world standard population. The trends were assessed by Joinpoint analysis. Results: A total of 9,440 incident cases were identified. The ASR was 3.4/105 for all sarcomas combined. Incidence of sarcomas overall was similar in females (3.5/105) as in males (3.4/105). Except for sarcomas "Not Otherwise Specified" (NOS), the most common histological subtype was gastrointestinal stromal sarcoma (GISS) (14.8%), which was followed by fibrosarcoma (7.2%), lipoblastoma (6.7%), leiomyosarcomas (6.5%), and osteosarcoma (5.3%). Among those incident cases, 87.9% were located in soft tissue sarcomas (STS) and 12.1% in bone and joint (bone sarcomas). The ASRs for STS and bone sarcomas were 2.8/105 and 0.6/105, respectively. Incidence rates for all STS combined rose exponentially with age, while bone sarcomas had the highest incidence at age 0-19. There were 4,279 deaths during 2002-2014 with the ASR of 1.3/105. Age-adjusted mortality due to sarcomas was slightly higher in males (1.5/105) than females (1.2/105). Except for sarcomas NOS, leiomyosarcomas was the most common subtype, comprising 9.9% of deaths due to sarcomas, followed by lipoblastoma (6.4%) and osteosarcoma (6.3%). The ASRs of mortality for STS and bone sarcomas were 1.0/105 and 0.2/105, respectively. For both males and females, the age-standardized incidence for STS and bone sarcomas did not change meaningfully over the study period. In contrast, age-standardized STS mortality in females increased by 2.3% per year (95% CI: 0.3, 4.4%), but was unchanged in males. No meaningful trends in bone sarcomas mortality were observed for either males or females. Conclusion: This population-based study was the first report of epidemiology of sarcomas in Shanghai according to anatomic site and histologic type. The diversity and rarity of sarcomas suggested more detailed data are warranted.
Collapse
Affiliation(s)
- Bao Pingping
- Department of Cancer Control and Prevention, Shanghai Municipal Center for Disease Prevention and Control, Shanghai, China
| | - Zhou Yuhong
- Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Lu Weiqi
- Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Wu Chunxiao
- Department of Cancer Control and Prevention, Shanghai Municipal Center for Disease Prevention and Control, Shanghai, China
| | - Wang Chunfang
- Department of Cancer Control and Prevention, Shanghai Municipal Center for Disease Prevention and Control, Shanghai, China
| | - Sun Yuanjue
- Department of Medical Oncology, Sixth People's Hospital South Campus, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Zhang Chenping
- Department of Oral and Maxillofacial Surgery, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Xiao Jianru
- Department of Bone Tumor Surgery, Shanghai Changzheng Hospital, Shanghai, China
| | - Lu Jiade
- Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai Cancer Hospital, Fudan University, Shanghai, China
| | - Kong Lin
- Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai Cancer Hospital, Fudan University, Shanghai, China
| | - Cai Zhengdong
- Department of Orthopedics, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Zhang Weibin
- Department of Orthopedics, Shanghai Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Fu Chen
- Shanghai Municipal Center for Disease Prevention and Control, Shanghai, China
| | - Yao Yang
- Department of Medical Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
| |
Collapse
|